Previsioni

Il prezzo obiettivo medio degli analisti è +93,00€ (−22,22%). La mediana è +105,19€ (−12,03%).

Acquista	8
Mantieni	16
Vendi	4

Notizie Vai al feed delle notizie

Moderna: $10,000 investment a year ago would have grown to $59,625.50 (+496.25%)

If $10,000 had been invested in Moderna a year ago (closing price $25.10), the 398.406 shares held on August 26, 2026, at a closing price of $149.66 would be worth $59,625.50, a performance of +496.25%. Moderna is most recently valued at about $63.41 billion. Stock splits and dividends are not included in the calculation. » Altro su finanzen.net
Moderna plans issuance of $2 billion convertible notes due 2032

Moderna announced a private placement of senior, unsecured convertible notes with an aggregate principal amount of $2.0 billion maturing in 2032, with a 13-day greenshoe option of up to $300 million. The notes pay no ongoing interest; upon conversion Moderna may, at its option, settle in cash, shares or a combination. Net proceeds are intended for capped-call transactions and general corporate purposes, including expansion of its oncology business and debt reduction. The capped-call transactions are intended to mitigate dilution; the initial cap price will be at least 150% above the last closing price on the pricing date. » Altro su de.investing.com
Moderna plans $2.0 billion convertible note offering – shares fall

Moderna announced a private placement of senior, unsecured convertible notes totaling $2.0 billion due 2032, plus a 13-day option for up to $300 million. The notes will be offered to qualified institutional buyers under Rule 144A, do not pay regular interest, and may be settled upon conversion in cash, common stock, or a combination of both. Net proceeds are to be used for general corporate purposes, including expanding the oncology business, repaying indebtedness, and financing capped-call hedging, with the initial cap price to be at least 150% above the last reported share price; the announcement pushed the stock down by about 5%. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, Moderna Inc. ha già distribuito 0,17€ di dividendi. L'ultimo pagamento è avvenuto a maggio 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Moderna Inc. ha registrato ricavi pari a 127.05m€ e un utile netto di −685.20m€

(EUR)	giu 2026	YoY
Ricavi	+127.05m	5,46%
Utile lordo	+45.56m	133,49%
Utile netto	−685.20m	2,11%
EBITDA	−616.85m	4,33%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+54.12b€
Numero di azioni	396.79m
Massimo/minimo a 52 settimane	+151,69€ - +19,13€
Dividendi	No
Beta	0,9
Rapporto P/E	−19,90
Rapporto PEG	+2,36
Rapporto P/B	+9,30
Rapporto P/S	+28,29

Profilo aziendale

Moderna, Inc., ein Biotechnologieunternehmen, entdeckt, entwickelt und vermarktet Boten-RNA-Therapeutika und Impfstoffe zur Behandlung von Infektionskrankheiten, Immunonkologie, seltenen Krankheiten, Herz-Kreislauf-Erkrankungen und Autoimmunerkrankungen in den Vereinigten Staaten, Europa und international. Die Impfstoffe gegen Atemwegserkrankungen umfassen COVID-19, Grippe, Respiratory Syncytial Virus, Endemic HCoV und hMPV+PIV3; die latenten Impfstoffe umfassen Cytomegalovirus, Epstein-Barr-Virus, Humanes Immundefizienz-Virus, Herpes-Simplex-Virus und Varizella-Zoster-Virus; und die Impfstoffe für die öffentliche Gesundheit bestehen aus Zika- und Nipah-Impfstoffen. Das Unternehmen bietet auch systemische sekretorische und Zelloberflächentherapeutika, Krebsimpfstoffe wie personalisierte Krebs-, KRAS- und Checkpoint-Impfstoffe, intratumorale Immuno-Onkologieprodukte, lokalisierte regenerative, systemische intrazelluläre und inhalative pulmonale Therapeutika an. Das Unternehmen unterhält strategische Allianzen mit AstraZeneca PLC, Merck & Co, Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc; Metagenomi, Inc; der Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; und der Bill & Melinda Gates Foundation sowie eine Kooperations- und Lizenzvereinbarung mit Chiesi Farmaceutici S.P.A. Das Unternehmen war früher als Moderna Therapeutics, Inc. bekannt und änderte im August 2018 seinen Namen in Moderna, Inc. Moderna, Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Nome	Moderna Inc.
CEO	Stéphane Bancel
Sede centrale	Cambridge, ma Stati Uniti
Sito web	investors.modernatx.com/overview/default.aspx
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	07/12/2018
Dipendenti	4.700